Alida Biosciences Announces Series A Funding and Early Access Launch of Innovative Products for Epitranscriptomic Research
Summary
SAN DIEGO, June 12, 2024 /PRNewswire/ -- Alida Biosciences (AlidaBio), an innovator in epigenomic research tools, proudly announces the successful completion of a $7.5 million Series A funding round. "The AlidaBio EpiPlex Library Prep Kit proved to have several advantages over alternative methods," said beta customer Dr. Daniel Kupers of Fred Hutchinson Cancer Research Center. This efficiency, driven by the NABs high affinity and specificity, ensures high-quality modification site calling without increasing sequencing depth requirements.The successful Series A funding for AlidaBio underscores investor confidence in the innovative approach. The strong support from our investors reflects our shared enthusiasm in building research tools needed to uncover new insights into RNA biology and advance the field of epitranscriptomics. "AlidaBio has created a technical yet elegant solution to uncover hidden regulatory information on RNA, scalable with current NGS technology," said Landon Merrill, principal at Genoa Ventures.